Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:ABT
  • CUSIP: 00282410
  • Web:
  • Market Cap: $94.92 billion
  • Outstanding Shares: 1,737,443,000
Average Prices:
  • 50 Day Moving Avg: $52.59
  • 200 Day Moving Avg: $48.17
  • 52 Week Range: $37.38 - $55.43
  • Trailing P/E Ratio: 85.36
  • Foreward P/E Ratio: 19.51
  • P/E Growth: 1.95
Sales & Book Value:
  • Annual Revenue: $23.61 billion
  • Price / Sales: 4.02
  • Book Value: $18.19 per share
  • Price / Book: 3.00
  • Annual Dividend: $1.06
  • Dividend Yield: 1.9%
  • EBITDA: $5.14 billion
  • Net Margins: 4.96%
  • Return on Equity: 14.43%
  • Return on Assets: 6.47%
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 2.94%
  • Quick Ratio: 2.41%
  • Average Volume: 5.53 million shs.
  • Beta: 1.06
  • Short Ratio: 2.35

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, September 15th. Stockholders of record on Friday, October 13th will be paid a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.94%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its earnings results on Thursday, July, 20th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. The business earned $6.64 billion during the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. Abbott Laboratories's quarterly revenue was up 24.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.55 EPS. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, October, 18th 2017. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its third quarter earnings guidance on Thursday, July, 20th. The company provided EPS guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 equities research analysts have issued 1 year price targets for Abbott Laboratories' shares. Their forecasts range from $42.00 to $64.00. On average, they anticipate Abbott Laboratories' share price to reach $55.50 in the next year. View Analyst Ratings for Abbott Laboratories.

What are analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • 1. According to Zacks Investment Research, "Over the past three months, Abbott has been trading above the broader industry. While we await Abbott's third-quarter 2017 earnings result, the promising full year guidance is indicative of brighter prospects ahead. In fact, the strong guidance is backed by the company’s expectations to gain more synergies from the St. Jude merger. Overall, we look forward to Abbott’s plans to expand in core therapeutic areas. Recently, the company's FreeStyle Libre Flash received the FDA approval. Also, the company has received FDA approval for magnetic resonance-conditional labeling for its Ellipse implantable cardioverter defibrillator recently. On the flip side, Abbott’s sluggish pediatric business in China continues to dent growth. Management is also concerned about the economic problems in Venezuela that are expected to remain unresolved for some time. Meanwhile, we still wait for the Alere integration details." (10/16/2017)
  • 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary
  • Stephen R. Fussell, Executive Vice President - Human Resources
  • Brian J. Blaser, Executive Vice President - Diagnostics Products
  • John M. Capek Ph.D., Executive Vice President - Ventures
  • Robert B. Ford, Executive Vice President - Medical Devices
  • Heather L. Mason, Executive Vice President - Nutritional Products
  • Roger Bird, Senior Vice President - U.S. Nutrition

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.03%), Osborn Williams & Donohoe LLC (0.01%), Bath Savings Trust Co (0.00%), McQueen Ball & Associates Inc. (0.00%), Curbstone Financial Management Corp (0.00%) and Bridges Investment Counsel Inc. (0.00%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Private Asset Management Inc., Osborn Williams & Donohoe LLC, Eqis Capital Management Inc. and Bath Savings Trust Co. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp, Park National Corp OH and McQueen Ball & Associates Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $54.63.

MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  579 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  1,008
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $55.50 (1.59% upside)
Consensus Price Target History for Abbott Laboratories (NYSE:ABT)
Price Target History for Abbott Laboratories (NYSE:ABT)
Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017J P Morgan Chase & CoInitiated CoverageNeutral -> Neutral$60.00N/AView Rating Details
10/4/2017Bank of America CorpReiterated RatingBuy$56.00 -> $60.00N/AView Rating Details
10/3/2017Royal Bank Of CanadaReiterated RatingBuy$55.00LowView Rating Details
10/2/2017BMO Capital MarketsReiterated RatingHold$53.00LowView Rating Details
9/28/2017Barclays PLCBoost Price TargetOverweight$57.00 -> $60.00LowView Rating Details
9/28/2017Wells Fargo & CompanyBoost Price TargetOutperform$57.00 -> $64.00LowView Rating Details
9/24/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
8/17/2017Citigroup Inc.Initiated CoverageNeutral -> Neutral$53.00MediumView Rating Details
8/3/2017Jefferies Group LLCReiterated RatingBuy$58.00LowView Rating Details
7/21/2017Stifel NicolausReiterated RatingBuy$58.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
6/29/2017GuggenheimInitiated CoverageBuy$58.00LowView Rating Details
6/21/2017BTIG ResearchInitiated CoverageBuy$56.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$45.00LowView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/16/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/18/2017$0.66N/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.63 billion$6.64 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20173$0.59$0.61$0.60
Q3 20173$0.64$0.68$0.66
Q4 20173$0.72$0.73$0.73
Q1 20182$0.55$0.56$0.56
Q2 20182$0.69$0.71$0.70
Q3 20182$0.74$0.76$0.75
Q4 20182$0.80$0.84$0.82
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Next Dividend:11/15/2017
Annual Dividend:$1.06
Dividend Yield:1.94%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:149.30% (Trailing 12 Months of Earnings)
42.57% (Based on This Year's Estimates)
37.86% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.45%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2017Daniel Gesua Sive SalvadoriInsiderSell62,460$52.95$3,307,257.00View SEC Filing  
9/22/2017Jaime ContrerasInsiderSell52,700$51.97$2,738,819.00View SEC Filing  
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.00View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.44View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
DateHeadline logoZacks Investment Research Downgrades Abbott Laboratories (ABT) to Hold - October 14 at 6:28 PM logoAssessing Abbott’s 3Q17 Expectations by Segment - October 13 at 3:18 PM logoAbbott Banks on FDA Approvals and Buyouts, Competition Rife - October 13 at 3:18 PM logoAbbott’s Analyst Recommendations ahead of Its 3Q17 Results - October 12 at 8:37 PM logoInside Abbott’s 3Q17 Revenue Expectations: Hit or Miss? - October 12 at 3:32 PM logoWhat to Expect from Abbott Laboratories’ 3Q17 Earnings - October 12 at 3:32 PM logoAbbott Laboratories (ABT) Receives Consensus Rating of "Buy" from Analysts - October 12 at 8:08 AM logoComparing Abbott Laboratories (ABT) & XenoPort (XNPT) - October 12 at 4:32 AM logoAbbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2017 - Nasdaq - October 11 at 3:35 PM logoDividend Coverage: This Healthcare Company has Paid Consecutive Quarterly Divided Since 1924; Will Trade Ex-Dividend on October 12, 2017 - October 11 at 3:35 PM logoIs a Beat in Store for Abbott (ABT) This Earnings Season? - October 11 at 3:35 PM logoExpress Scripts (ESRX) to Buy eviCore, Fortify PBM Business - October 11 at 3:35 PM logoQIAGEN Banks on Tie-Ups & Product Launches, Competition Rife - October 11 at 3:35 PM logoAbbott Laboratories (ABT) Scheduled to Post Earnings on Wednesday - October 11 at 1:38 AM logoAbbott Laboratories (ABT) Raised to Buy at Zacks Investment Research - October 10 at 11:26 PM logoEx-Dividend Reminder: Abbott Laboratories, Becton, Dickinson and Pennymac Mortgage Investment Trust - Nasdaq - October 10 at 3:30 PM logoAbbott Laboratories (ABT) Raised to Buy from a Hold | InvestorPlace - - October 10 at 3:30 PM logoIllumina (ILMN) Strong on Product Launches, Competition Rife - October 10 at 3:30 PM logoQIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite - October 10 at 3:30 PM logoStrategic Research Analysis ­ Positioning to Benefit on  Abbott, Rite Aid, Kroger, Celgene, Twitter, and NIKE ­ Effects of Key Drivers of Growth and Emerging Market Trends - October 10 at 3:30 PM logoPfizer weighs $15 bln sale of consumer healthcare business - October 10 at 3:30 PM logoDividend Aristocrats In Focus Part 6: Abbott Laboratories - October 9 at 3:35 PM logoPremarket analyst action - healthcare - Abbott Laboratories (NYSE ... - Seeking Alpha - October 8 at 3:17 PM logoAbbott Laboratories (ABT) Research Coverage Started at J P Morgan Chase & Co - October 7 at 3:36 PM logoContrasting Abbott Laboratories (ABT) & Adamis Pharmaceuticals Corp (ADMP) - October 6 at 10:36 PM logoAbbott Labs (ABT) PT Raised to $60 at BofA/Merrill Lynch - - October 5 at 3:12 PM logoAbbott Labs (ABT) PT Raised to $60 at BofA/Merrill Lynch - October 5 at 12:33 PM logo$0.65 EPS Expected for Abbott Laboratories (ABT) This Quarter - October 4 at 10:24 PM logoAbbott Laboratories' (ABT) "Buy" Rating Reiterated at Bank of America Corporation - October 4 at 7:14 PM logoReviewing Abbott Laboratories (ABT) & Its Peers - October 4 at 4:34 PM logoUS pressing India to avoid capping medical device prices, allow withdrawals - Reuters - October 4 at 8:13 AM logoAbbott Completes Cash Tender Offer for Series B Convertible Perpetual Preferred Stock of Alere Inc. - October 4 at 8:12 AM logoReading Abbott’s FDA Approval for MR-Conditional Labeling for Its Ellipse ICD - October 3 at 3:06 PM logoCan Abbott’s Latest Approval Accelerate Its Established Pharmaceuticals Business? - October 3 at 3:06 PM logoAbbott to Gain from Alere's Takeover Due for Oct 3 Closure - October 2 at 8:15 PM logoAbbott to Gain from Alere's Takeover Due for Oct 3 Closure - October 2 at 8:14 PM logoAbbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval - October 2 at 8:14 PM logoAbbott Laboratories (ABT) Receives "Hold" Rating from BMO Capital Markets - October 2 at 5:44 PM logoWhat’s Behind Abbott’s 52-Week High Rally? - October 2 at 3:12 PM logoReviewing Astrazeneca PLC (AZN) & Abbott Laboratories (ABT) - October 2 at 10:30 AM logoFTC requires Abbott (ABT) divestments for Alere (ALR) purchase - September 29 at 3:05 PM logoFTC Approves Abbott's Acquisition of Alere, Stock Jumps - September 29 at 10:30 AM logoToday's Research Reports on Stocks to Watch: Abbott Laboratories and DexCom - September 29 at 10:30 AM logoAbbott Laboratories (ABT) Rose To A New High After FDA Approval - September 29 at 10:30 AM logoAbbott Labs’ Billion-Dollar Product - September 29 at 10:30 AM logoAbbott, Alere, and Approvals, Oh My - September 29 at 10:30 AM logoAbbott Laboratories (ABT) Has Jumped To A New High After FDA Approval - September 28 at 8:34 PM logoDaniel Gesua Sive Salvadori Sells 62,460 Shares of Abbott Laboratories (ABT) Stock - September 28 at 7:24 PM logoAbbott wins US antitrust approval to buy Alere with conditions - Reuters - September 28 at 3:32 PM logoBuy Abbott Labs as It Obliterates DexCom Stock, Jim Cramer Says - - September 28 at 3:32 PM



Abbott Laboratories (ABT) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.